NeoGenomics, the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and the Northwestern Medicine Developmental Therapeutics Institute Launch Collaborative Translational Research Program
Press Release
Read More
Complete molecular risk stratification of de novo acute myeloid leukemia with intermediate cytogenetics using a nine-gene panel
Literature
Read More
Deep sequencing of peripheral blood plasma DNA as a reliable test for confirming the diagnosis of MDS
Literature
Read More
Determining tumor load and biallelic mutation in patients with CALR mutation using peripheral blood plasma
Literature
Read More
Molecular profiling in confirming the diagnosis of early myelodysplastic syndrome
Literature
Read More
NeoGenomics Reports 38% increase in Revenue to a Record $23.2 Million and Adjusted EBITDA of $2.6 Million for the Third Quarter of 2014
Press Release
Read More
NeoGenomics is First to Offer Molecular Testing for Resistance to Bruton Tyrosin Kinase Inhibitors for Chronic Lymphocytic Leukemia
Press Release
Read More
NeoGenomics Launches 315 Gene Next Generation Sequencing Test for Solid Tumor Discovery Profiling
Press Release
Read More